NCT06598384View on ClinicalTrials.gov

VA as Maintenance Therapy Post Allo-HSCT in MDS and AML

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2030

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax combined with Azacytidine

"Patients were treated by venetoclax and azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5."

All Listed Sponsors
lead

Navy General Hospital, Beijing

OTHER

NCT06598384 - VA as Maintenance Therapy Post Allo-HSCT in MDS and AML | Biotech Hunter | Biotech Hunter